Kintz Samuel's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Oct 8, 2024
- Accession no.
- 0001415889-24-024901
- Filed
- Oct 8, 2024
- Trade date
- Oct 4-7, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $410.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kintz SamuelCIK 0001967168 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 4, 2024 | Common Stock | SSaleDisposed | −12,206 | $27.51F2 | −$335,787.06 | 1,036,523 | Indirect | |
| Oct 7, 2024 | Common Stock | SSaleDisposed | −2,730 | $27.50 | −$75,075 | 1,033,793 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.